The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1210
Exenatide (Byetta) for Type 2 Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Exenatide injection (Byetta – Amylin/Lilly), a synthetic peptide that stimulates release of insulin from pancreatic beta cells, has been approved by the FDA as adjunctive therapy for patients with type 2 diabetes who have not achieved optimal glycemic control on metformin (Glucophage, and others), a sulfonylurea, such as glyburide (DiaBeta, and others), or both. Exenatide is not indicated for use with insulin.

MECHANISM OF ACTION — Several peptide hormones (incretins) are released from cells in the gastrointestinal tract in response to food. Glucagon-like peptide-1 (GLP-1) is one of these. Exenatide is a GLP-1 agonist (incretin mimetic); it potentiates insulin secretion, inhibits secretion of glucagon, slows gastric emptying and promotes satiety. In patients with diabetes, this results in modest lowering of fasting glucose and marked reduction of postprandial levels. Animal studies have ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Exenatide (Byetta) for Type 2 Diabetes
Article code: 1210a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian